Outlier consideration and re-dosing of Subjects [Regulatives / Guidelines]

posted by tripathy – 2006-07-21 06:06  – Posting: # 180
Views: 4,894

Dear Forum member,

I am a Pharmacokinetist. I am new to this forum.
I went through some of the discussion topics, I found them really useful and decided to become a member of this forum.

I would like to ask forum members regarding the Statistical outlier consideration and re-dosing of subjects in a BE study. Whether outliers and re-dosing of subjects are acceptable by US-FDA regulatory, if yes then I would be very greatful to you if you provide me the link to any such guidance or correspondance from US-FDA.

Thanks and Regards,
Tripathy

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,603 posts in 4,157 threads, 1,340 registered users;
online 8 (0 registered, 8 guests [including 5 identified bots]).
Forum time (Europe/Vienna): 00:44 CEST

Nothing in the world is more dangerous
than sincere ignorance
and conscientious stupidity.    Martin Luther King, Jr.

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5